Improving Metabolic Health in Patients With Diastolic Dysfunction

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-06-01

Study Completion Date

2019-07-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine whether 1 year of supervised exercise training in obese individuals at high risk for developing HF, incorporating high intensity interval training (HIIT) two to three times per week in conjunction with daily oral administration of omega-3 poly-unsaturated fatty acids will lead to reduction in visceral adiposity, regression of myocardial triglyceride levels and improvements in cardiac diastolic and vascular function.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Intervention With Omega Fatty Acids in High-risk Patients

NCT02647333

Cardiovascular Disease

COMPLETED PHASE2

Slowing HEART diSease With Lifestyle and Omega-3 Fatty Acids

NCT01624727

Coronary Heart Disease Metabolic Syndrome

COMPLETED NA

Effect of High Dose Fish Oil Supplementation After Recent Heart Attack Using Magnetic Resonance Imaging

NCT00729430

Myocardial Infarction Death, Sudden, Cardiac

COMPLETED PHASE3

Combining HIIT and n-3 PUFA to Reduce Inflammation and Improve Metabolic Health

NCT05295719

Obesity Inflammation Human Microbiome +2 more

COMPLETED NA

Intervention With Vitamin D and Omega-3 Supplements and Incident Heart Failure

NCT02271230

Heart Failure

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The global objective of this project is to test novel strategies to prevent obesity related abnormalities in diastolic function that may progress to heart failure with preserved ejection fraction (HFpEF). These include: a) identifying high risk individuals by using population derived imaging and blood biomarkers; and b) implementing novel exercise training and "nutri-ceutical" strategies in obese middle aged individuals with high amounts of visceral fat, an important risk factor in the development of heart failure and adverse cardiac remodeling.

Prior work has demonstrated that: a) high levels of myocardial triglyceride content are associated with a smaller and less distensible left ventricle with reduced tissue relaxation rates compared to those with low levels and b) low fitness and high body mass index were the strongest predictors of elevated myocardial content. The consequences of excess visceral adiposity (intra- and retro-peritoneal adipose tissue) on cardiac remodeling suggest individuals with high visceral fat content and low fitness are at particularly high risk for heart failure.

The primary objective of this project is therefore to identify high risk, sedentary, middle aged obese individuals with high visceral fat levels, and initiate an exercise program in conjunction with omega-3 fatty acid supplementation designed to reduce visceral adiposity and regress myocardial triglyceride accumulation. Findings from this aim would have enormous public health significance and establish a novel, practical exercise training program and "nutria-ceutical" strategy to reverse obesity related cardiovascular remodeling.

Hypothesis:

High aerobic exercise training in conjunction with daily omega-3 supplementation will reduce visceral myocardial triglyceride accumulation by reducing visceral adiposity. A reduction of myocardial fat will lead to improved LV structure and diastolic function by an approach that is not necessarily predicated on weight loss.

Specific Aim:

To test our hypothesis that reduction in myocardial triglyceride content will improve markers of diastolic function, we have designed a randomized, double blind, placebo controlled trial. We will study four groups of previously sedentary obese middle aged subjects at high risk for development of HF for one year with the following interventions: A) sedentary controls taking placebo; B) sedentary subjects taking omega-3 fatty acids; C) subjects undergoing high intensity aerobic exercise training while on placebo and D) subjects undergoing high intensity aerobic exercise training while taking omega-3 fatty acids. Subjects will be categorized as high risk and enrolled on the basis of elevated serum biomarkers (cTnT) and high visceral fat content (\>2.5 kg). We will perform comprehensive non-invasive assessments of cardiovascular structure and systolic/diastolic function before and after 1 year of an exercise intervention involving high intensity intervals and omega-3 administration. We anticipate the combination of high intensity aerobic exercise in conjunction with high dose omega-3 supplementation will reduce visceral adiposity, decrease myocardial triglyceride content and improve markers of diastolic and vascular function.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obesity Heart Failure, Diastolic Metabolic Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

FACTORIAL

2x2 factorial design. Subjects are randomized to aerobic exercise or yoga as well as high dose omega-3 fatty acids or olive oil placebo.

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Subjects and investigative team (except for statistician) are blinded to omega-3 vs olive oil placebo. Subjects and investigators are aware of exercise modality. Outcomes assessors are blinded to all aspects of subject randomization.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control

Subjects randomized to control group will receive olive oil placebo capsules and yoga intervention for 1 year.

Group Type PLACEBO_COMPARATOR

Yoga

Intervention Type BEHAVIORAL

Subjects randomized to yoga will undergo yoga training as a control to those randomized to high intensity aerobic exercise.

olive oil capsules

Intervention Type DIETARY_SUPPLEMENT

Subjects randomized to receive olive oil placebo will take 1 gram total of olive oil capsule per day.

Exercise and omega-3 fatty acids

Subjects will receive high dose omega-3 fatty acids as well as aerobic exercise intervention for 1 year.

Group Type EXPERIMENTAL

High intensity exercise

Intervention Type BEHAVIORAL

Subjects will be randomized to the exercise groups will undergo 1 year aerobic exercise training comprised of high intensity exercise sessions 2-3 days per week. Sessions will be supervised remotely via heart rate monitors.

Omega-3 fish oil

Intervention Type DIETARY_SUPPLEMENT

Subjects randomized to omega-3 fatty acids will take 2 grams total of omega-3 per day for 1 year.

Yoga and omega-3 fatty acids

Subjects will receive high dose omega-3 fatty acids as well as yoga intervention for 1 year.

Group Type ACTIVE_COMPARATOR

Omega-3 fish oil

Intervention Type DIETARY_SUPPLEMENT

Subjects randomized to omega-3 fatty acids will take 2 grams total of omega-3 per day for 1 year.

Yoga

Intervention Type BEHAVIORAL

Subjects randomized to yoga will undergo yoga training as a control to those randomized to high intensity aerobic exercise.

Exercise control

Subjects will receive olive oil placebo as well as aerobic exercise intervention for 1 year.

Group Type ACTIVE_COMPARATOR

High intensity exercise

Intervention Type BEHAVIORAL

Subjects will be randomized to the exercise groups will undergo 1 year aerobic exercise training comprised of high intensity exercise sessions 2-3 days per week. Sessions will be supervised remotely via heart rate monitors.

olive oil capsules

Intervention Type DIETARY_SUPPLEMENT

Subjects randomized to receive olive oil placebo will take 1 gram total of olive oil capsule per day.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

High intensity exercise

Subjects will be randomized to the exercise groups will undergo 1 year aerobic exercise training comprised of high intensity exercise sessions 2-3 days per week. Sessions will be supervised remotely via heart rate monitors.

Intervention Type BEHAVIORAL

Omega-3 fish oil

Subjects randomized to omega-3 fatty acids will take 2 grams total of omega-3 per day for 1 year.

Intervention Type DIETARY_SUPPLEMENT

Yoga

Subjects randomized to yoga will undergo yoga training as a control to those randomized to high intensity aerobic exercise.

Intervention Type BEHAVIORAL

olive oil capsules

Subjects randomized to receive olive oil placebo will take 1 gram total of olive oil capsule per day.

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. ejection fraction \>0.50
2. \>2.0 kg visceral fat (intra- and retro-peritoneal adipose tissue)
3. either a high sensitivity troponin (\>0.6pg/ml), or NTBNP (\>40 ng/ml)
4. age range 40 -60
5. BMI range 30 - 50 kg/m2

Exclusion Criteria

1. age \< 40 or \> 60
2. body mass index \> 50, \< 30 kg/m2
3. history of insulin dependent diabetes, heart failure, myocarditis, restrictive cardiomyopathy, permanent/persistent atrial fibrillation, severe chronic obstructive pulmonary disease, unstable coronary artery disease or recent (\<12 month) acute coronary syndrome, cerebrovascular disease as evidenced by prior transient ischemic attack or stroke and active/recent tobacco use (quit \< 5 years).
4. Female patients will be excluded if they are pregnant or plan to become pregnant (expected rare occurrence in the selected age range of 40 - 60). 5. Patients will be excluded if they are taking non-statin lipid lowering agents (fibrates, niacin, or fish oils)
5. Contra-indications to MRI

Minimum Eligible Age

40 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes